In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 43 for your search:
Cancer Type/Condition:  Soft tissue sarcoma, adult
Stage/Subtype:  recurrent adult soft tissue sarcoma
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR003583, ET743SAR3002, NCT00210665

2.

Phase: Phase III
Type: Treatment
Status: Active
Age: 15 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ALDOXORUBICIN-P3-STS-01, NCT02049905

3.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: AVF4761s, 200911736, NCT01106872

4.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-01412, CDR0000680558, MSKCC-10049, 10-049, 8406, U01CA069856, P30CA008748, NCT01154452

5.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BBI608-201, NCT01325441

6.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 12 and over
Sponsor: Other
Protocol IDs: 2010-0700, NCI-2012-00788, NCT01590069

7.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 12-100, NCT01659203

8.

Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 25 and under for new enrollments only
Sponsor: Other
Protocol IDs: RTSARC, NCT00186992

9.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: 05-122, MSKCC-05122, NCT00445965

10.

Phase: Phase II
Type: Treatment
Status: Active
Age: 30 and under
Sponsor: NCI, Other
Protocol IDs: 05-326, Other, NCT00592293

11.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 08-1299 / 201109179, NCT00802880

12.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 090192, 09-C-0192, NCT00942877

13.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 10-094, NCT01209598

14.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ACORN ABLSMLS1101, NCT01506596

15.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 90
Sponsor: Other
Protocol IDs: MUSC 101644, PAZ115785, NCT01593748

16.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01991, CDR0000737403, CALGB-A091102, A091102, U10CA180821, U10CA031946, NCT01653028

17.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 130044, 13-C-0044, NCT01755195

18.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NU 12S02, NCI-2012-03188, STU00073826, NCT01782313

19.

Phase: Phase II
Type: Treatment
Status: Active
Age: 0 to 40
Sponsor: Other
Protocol IDs: J12106, NCT01804634

20.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Carter 2005-01, 1073869, NCT01898962

21.

Phase: Phase II
Type: Treatment
Status: Active
Age: 14 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: HS13-00655, BB-43984, NCT01984892

22.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: NU 13S02, NCI-2013-02278, STU00087654, ONC-2013-129, P30CA060553, NCT02048722

23.

Phase: Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI, Other
Protocol IDs: 03-133, P30CA008748, MSKCC-03133, NCT00089245

24.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 and over
Sponsor: Other
Protocol IDs: 09-090, NCT01099644

25.

Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 110111, 11-C-0111, NCT01313429
1   
New Search